Eftekharian Kourosh, Najafi Elnaz, Amizadeh Maryam, Mokari Noosheen, Faramarzi Mohammad, Izadparast Yalda, Jabbari Moghadam Yalda, Eftekharian Ali
Hearing Disorders Research Center, Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences Tehran Iran.
Department of Otolaryngology-Head and Neck Surgery, School of Medicine Stanford University USA.
Laryngoscope Investig Otolaryngol. 2024 Dec 17;9(6):e70054. doi: 10.1002/lio2.70054. eCollection 2024 Dec.
To compare the hearing outcomes of patients with idiopathic sudden sensorineural hearing loss after intratympanic (IT) injection of methylprednisolone and dexamethasone.
Randomized case-controlled clinical trial.
Seventy-five patients diagnosed with idiopathic sensorineural hearing loss were randomly divided into two groups based on therapy. Both groups received oral prednisolone (10 mg/kg; maximum of 60 mg) for 10 days without tapering and received IT injections two times a week for 2 weeks (four injections in total). One group received an IT injection of a 40 mg/mL solution of methylprednisolone, and the other one, 4 mg/mL dexamethasone. Three comparisons between the initial and third-month hearing tests were made to assess the degree of hearing change: (1) pure tone improvement in each individual tone (0.5, 1, 2, 3, and 4 kHz); (2) word-recognition score improvement; and (3) complete, partial, and no recovery of hearing calculated (as defined by American Academy of Otolaryngology-Head and Neck Surgery Clinical Practice Guidelines).
The study was completed with 69 of the 75 patients-34 in the methylprednisolone group and 35 in the dexamethasone group. The groups' differences in frequency-specific hearing improvement were not statistically significant. There was no statistically significant difference in the word recognition score improvement between the two groups. Additionally, there was no discernible difference between the two groups' hearing recovery rates.
Methylprednisolone and dexamethasone IT injection therapy had similar hearing outcomes.
比较鼓室内注射甲泼尼龙和地塞米松治疗特发性突发性感音神经性听力损失患者的听力结果。
随机病例对照临床试验。
75例被诊断为特发性感音神经性听力损失的患者根据治疗方法随机分为两组。两组均接受口服泼尼松龙（10mg/kg；最大剂量60mg），持续10天，不减量，并每周接受2次鼓室内注射，共2周（总共4次注射）。一组接受鼓室内注射40mg/mL的甲泼尼龙溶液，另一组接受4mg/mL的地塞米松。在初次听力测试和第三个月听力测试之间进行三项比较，以评估听力变化程度：（1）每个单音（0.5、1、2、3和4kHz）的纯音改善情况；（2）单词识别分数的改善情况；（3）计算听力的完全恢复、部分恢复和未恢复情况（根据美国耳鼻咽喉头颈外科学会临床实践指南定义）。
75例患者中有69例完成了研究，其中甲泼尼龙组34例，地塞米松组35例。两组在特定频率听力改善方面的差异无统计学意义。两组在单词识别分数改善方面无统计学显著差异。此外，两组的听力恢复率之间没有明显差异。
鼓室内注射甲泼尼龙和地塞米松治疗的听力结果相似。
2级。
